As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use

Mariko Shimizu, Vice President, Obesity Business Unit, Novo Nordisk Japan Novo Nordisk Pharma launched its GLP-1 receptor agonist Wegovy (semaglutide) on February 22, making it the first obesity drug in over three decades to be made available in Japan. Upon...read more